Jiangsu Nhwa Pharmaceutical Co., Ltd. Class ASZSE: 002262

Jiangsu Nhwa Pharmaceutical: Q3 2024 saw double-digit revenue and profit growth, with robust cash flow and rising EPS

· Issued by Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A

Q3 2024 revenue grew 10.07% and net profit rose 14.74% year-over-year, with strong cash flow and higher EPS. Asset and equity growth were supported by increased investment and a stock incentive plan.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis

Earlier from Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A

All Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A news releases